BetterScholar BetterScholar

P. Laeis

Journal of Hypertension - Supplement, The Lancet, New England Journal of Medicine, Therapeutic Advances in Cardiovascular Disease, Thrombosis and Haemostasis, Journal of Hypertension, European Heart Journal - Cardiovascular Pharmacotherapy, Clinical drug investigation Show more
10
Role
Title
Level Year L/R
🐜 Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial
16 auth. P. Vranckx, M. Valgimigli, L. Eckardt, J. Tijssen, T. Lewalter, G. Gargiulo, V. Batushkin, G. Campo, Z. Lysak, I. Vakaliuk, ... K. Milewski, P. Laeis, P. Reimitz, R. Smolnik, W. Zierhut, A. Goette 		8 2019
8
🐜
🦁 The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction
P. Laeis, K. Püchler, W. Kirch 		7 2001
7
🦁
🐜 Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
36 auth. N. Van Mieghem, M. Unverdorben, C. Hengstenberg, H. Möllmann, R. Mehran, D. Lopez-Otero, L. Nombela‐Franco, R. Moreno, P. Nordbeck, H. Thiele, I. Lang, J. Zamorano, F. Shawl, M. Yamamoto, Y. Watanabe, ... K. Hayashida, R. Hambrecht, F. Meincke, P. Vranckx, James Jin, E. Boersma, J. Rodés‐Cabau, P. Ohlmann, P. Capranzano, Hyo‐Soo Kim, T. Pilgrim, Richard Anderson, U. Baber, A. Duggal, P. Laeis, H. Lanz, Cathy Chen, M. Valgimigli, R. Veltkamp, S. Saito, G. Dangas 		7 2021
7
🐜
🐜 Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study.
8 auth. K. Stumpe, E. Agabiti-Rosei, T. Zieliński, D. Schremmer, J. Scholze, P. Laeis, ... P. Schwandt, M. Ludwig 		6 2007
6
🐜
🐜 The management of acute venous thromboembolism in clinical practice
10 auth. A. Cohen, A. Gitt, R. Bauersachs, E. Fronk, P. Laeis, P. Mismetti, ... M. Monreal, S. Willich, P. Bramlage, G. Agnelli 		6 2017
6
🐜
🐬 Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil
K. von Bergmann, P. Laeis, K. Püchler, T. Sudhop, L. Schwocho, Lisette Gonzalez 		6 2001
6
🐬
🐬 Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist
K. Püchler, P. Laeis, K. Stumpe 		5 2001
5
🐬
🐬 Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension
L. Sellin, J. Stegbauer, P. Laeis, L. Rump 		5 2005
5
🐬
🐜 Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study
17 auth. J. D. de Groot, T. Weiss, P. Kelly, P. Monteiro, J. Deharo, C. de Asmundis, E. Lopez-de-Sa, J. Waltenberger, J. Steffel, P. Levy, ... A. Bakhai, W. Zierhut, P. Laeis, M. Manu, P. Reimitz, R. de Caterina, P. Kirchhof 		5 2020
5
🐜
🐢 Efficacy and Safety of Triple Antihypertensive Therapy with the Olmesartan/Amlodipine/Hydrochlorothiazide Combination
M. Volpe, L. Rump, B. Ammentorp, P. Laeis 		5 2012
5
🐢